Search results for " KAP"

showing 10 items of 266 documents

Convergent sets of data from in vivo and in vitro methods point to an active role of Hsp60 in chronic obstructive pulmonary disease pathogenesis.

2011

BackgroundIt is increasingly clear that some heat shock proteins (Hsps) play a role in inflammation. Here, we report results showing participation of Hsp60 in the pathogenesis of chronic obstructive pulmonary diseases (COPD), as indicated by data from both in vivo and in vitro analyses.Methods and resultsBronchial biopsies from patients with stable COPD, smoker controls with normal lung function, and non-smoker controls were studied. We quantified by immunohistochemistry levels of Hsp10, Hsp27, Hsp40, Hsp60, Hsp70, Hsp90, and HSF-1, along with levels of inflammatory markers. Hsp10, Hsp40, and Hsp60 were increased during progression of disease. We found also a positive correlation between th…

MaleSTRESSPulmonologyChronic Obstructive Pulmonary DiseasesNeutrophilsBiopsyGene ExpressionCD8-Positive T-Lymphocytesmedicine.disease_causeBiochemistryEpitheliumPulmonary function testingPathogenesisACTIVATIONPulmonary Disease Chronic ObstructiveMolecular Cell BiologyLungCOPDMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionCOPD Hsp60QRCOPD heat shock proteins inflammationMiddle AgedImmunohistochemistrymedicine.anatomical_structureEXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITISMedicineFemalemedicine.symptomInflammation MediatorsSPINAL-CORDResearch ArticleEXPRESSIONanimal structuresCOPD; heat shock proteins; inflammationScienceImmunologyMolecular Sequence DataInflammationBronchichemical and pharmacologic phenomenaHEAT-SHOCK-PROTEIN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS ACUTE LUNG INJURY SPINAL-CORD CELL-DEATH KAPPA-B HEAT-SHOCK-PROTEIN-60 STRESS EXPRESSION ACTIVATIONKAPPA-BBiologyHEAT-SHOCK-PROTEINMicrobiologycomplex mixturesCell LineACUTE LUNG INJURYMolecular GeneticsIn vivoStress PhysiologicalHeat shock proteinmedicineGeneticsHumansCOPDRNA MessengerBiologyAgedLungMucous MembraneBase SequenceSettore BIO/16 - Anatomia UmanaMacrophagesfungiImmunityTranscription Factor RelAProteinsComputational BiologyChaperonin 60medicine.diseaseChaperone Proteinsrespiratory tract diseasesGene Expression RegulationCELL-DEATHHEAT-SHOCK-PROTEIN-60inflammationImmunologyheat shock proteinsClinical ImmunologyOxidative stressBiomarkers
researchProduct

Localisation of mediterranean Kaposi's sarcoma in Morgagni's ventricle

2011

Objective: Head and neck involvement in Kaposi’s Sarcoma (KS) is not unusual . However, laryngeal involvement is a relatively infrequent manifestation and ENT specialists should consider it in differential diagnosis in laryngeal lesions of AIDS patients and/or subjects from the Mediterranean area. Methods: Case report and review of the literature in English Clinical Case: Male patient presenting with a three- month history of cough and acute dispnoea. Laryngoscopy identified a laryngeal mass occluding the glottic plane. Tracheotomy was then performed and the laryngeal lesion was removed. Histopathology showed neoplastic spindle cells that were positive to immunostain with CD-31 and CD-34, a…

MaleSettore MED/31 - OtorinolaringoiatriaSettore MED/06 - Oncologia MedicaHumansLarynx Kaposi's sarcoma larynx surgery histopathology morgagni's ventricleImmunohistochemistryLaryngeal NeoplasmsSarcoma KaposiAged
researchProduct

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspi…

2009

The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control …

MaleThalassemiaKaplan-Meier Estimatelaw.inventionchemistry.chemical_compoundRandomized controlled triallawCause of DeathNeoplasmsDeferiproneProspective StudiesChildCause of deathHazard ratioHematologyMiddle AgedCombined Modality TherapySurvival RateThalassemia survival chelation treatment trial thalassemia majorCombinationSplenectomyMolecular MedicineDrug Therapy CombinationFemaleDeferiproneAdultmedicine.medical_specialtyAdolescentPyridonesDeferoxamineIron Chelating AgentsYoung AdultDrug TherapyInternal medicinemedicineHumansBlood TransfusionAdolescent; Adult; Blood Transfusion; Cause of Death; Chelation Therapy; Child; Combined Modality Therapy; Deferoxamine; Drug Therapy; Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Kaplan-Meiers Estimate; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prospective Studies; Pyridones; Splenectomy; Survival Rate; Young Adult; beta-ThalassemiaMolecular BiologySurvival rateKaplan-Meiers EstimateSurvival analysisProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modelbeta-ThalassemiaCell Biologymedicine.diseaseChelation TherapySurgerychemistrybusiness
researchProduct

Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Regist…

2012

Objective.To evaluate 4-year retention rates of tumor necrosis factor-α (TNF-α) inhibitors adalimumab, etanercept, and infliximab among patients with longstanding rheumatoid arthritis (RA), as derived from an Italian national registry.Methods.The clinical records of 853 adult patients with RA in the GISEA (Gruppo Italiano Studio Early Arthritis) registry were prospectively analyzed to compare drug survival rates and the baseline factors that may predict adherence to therapy.Results.In 2003 and 2004, 324 patients started treatment with adalimumab, 311 with etanercept, and 218 with infliximab. After 4 years, the global retention rate of anti-TNF-α therapy was 42%. Etanercept survival (51.4%) …

MaleTime FactorsHealth StatusArthritisKaplan-Meier EstimateReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptArthritis RheumatoidRandomized controlled triallawRheumatoidMonoclonalReceptorsImmunology and AllergyProspective StudiesRegistriesskin and connective tissue diseasesProspective cohort studyHumanizedAntibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biological Markers; Drug Substitution; Female; Health Status; Humans; Immunoglobulin G; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesPain MeasurementDrug SubstitutionAntibodies MonoclonalMiddle AgedArthralgiaAdalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; RegistriesSurvival RateItalyRheumatoid arthritisAntirheumatic AgentsBiological MarkersAdalimumab; Drug survival; Etanercept; Infliximab; Adalimumab; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthralgia; Arthritis Rheumatoid; Biomarkers; Drug Substitution; Etanercept; Female; Health Status; Humans; Immunoglobulin G; Infliximab; Italy; Joints; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors Tumor Necrosis Factor; Survival Rate; Time Factors; Tumor Necrosis Factor-alpha; Registries; Rheumatology; Immunology; Immunology and AllergyFemalemedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyImmunologyAntibodies Monoclonal HumanizedAntibodiesRheumatologyDrug survivalInternal medicineAdalimumabmedicineHumansSurvival ratebusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabInfliximabSurgeryImmunoglobulin GJointsbusinessTumor Necrosis FactorBiomarkers
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Papillary muscle relocation in conjunction with valve annuloplasty improve repair results in severe ischemic mitral regurgitation

2012

OBJECTIVE: The incidence of recurrent mitral regurgitation (MR) after restrictive annuloplasty (RA) was 5% to 20% in several reports. There are many opinions in favor of adding subvalvular procedures to RA to reduce the tenting forces and improve the repair results. METHODS: From March 2003 to May 2010, 55 patients with severe ischemic MR who had undergone papillary muscle (PPM) relocation in conjunction with mitral annuloplasty in our institutions were enrolled. The patients were matched 1:1 with those who underwent isolated RA using the propensity score. The mean left ventricular ejection fraction was 42% ± 6%. The mean tenting area and coaptation depth was 3.2 ± 0.6 cm(2) and 1.3 ± 0.2 c…

MaleTime FactorsMitral Valve AnnuloplastyLeftMyocardial IschemiaKaplan-Meier EstimateSeverity of Illness IndexVentricular Function LeftPapillary muscle annuloplasty mitral regurgitationPostoperative ComplicationsRisk FactorsMitral valve annuloplastyAged; Chi-Square Distribution; Disease-Free Survival; Female; Hospital Mortality; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Matched-Pair Analysis; Middle Aged; Mitral Valve Insufficiency; Myocardial Ischemia; Papillary Muscles; Postoperative Complications; Propensity Score; Proportional Hazards Models; Risk Assessment; Risk Factors; Secondary Prevention; Severity of Illness Index; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function Left; Mitral Valve AnnuloplastySecondary PreventionClinical endpointVentricular FunctionHospital MortalityMyocardial infarctionEjection fractionIncidence (epidemiology)Mitral Valve InsufficiencyMiddle AgedPapillary MusclesTreatment Outcomemedicine.anatomical_structureItalyCardiologyFemaleCardiology and Cardiovascular MedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMatched-Pair AnalysisRisk AssessmentDisease-Free SurvivalInternal medicinemedicineHumansPropensity ScorePapillary muscleAgedProportional Hazards ModelsMitral regurgitationChi-Square Distributionbusiness.industryStroke VolumeSettore MED/23 - Chirurgia Cardiacamedicine.diseaseSurgeryLogistic ModelsPropensity score matchingSurgerybusiness
researchProduct

Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study

2017

Essentials Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated. We studied 411 consecutive outpatients with acute iSVT with a median follow-up of three years. Male sex and cancer are risk factors for future deep vein thrombosis or pulmonary embolism. Patients without cancer appear to be at a negligible risk for death. SUMMARY Background Studies of long-term thromboembolic complications and death following acute isolated superficial vein thrombosis (iSVT) of the lower extremities are scarce. Objectives To investigate the course of iSVT in the setting of an observational multicenter study. Methods We collected longitudinal data of 411 consecutive outpati…

MaleTime FactorsSuperficial vein thrombosisDeep veinKaplan-Meier Estimate030204 cardiovascular system & hematology0302 clinical medicineRecurrenceRisk FactorsInterquartile rangecohort study; death; major bleeding; superficial vein thrombosis; venous thromboembolism; Adult; Aged; Anticoagulants; Cause of Death; Female; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Longitudinal Studies; Lower Extremity; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Proportional Hazards Models; Pulmonary Embolism; Recurrence; Retrospective Studies; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Venous ThrombosisCause of DeathNeoplasmssuperficial vein thrombosiOdds RatioLongitudinal StudiesCause of deathVenous ThrombosisIncidenceAnticoagulantHematologyMiddle AgedThrombosisPulmonary embolismVenous thrombosisTreatment Outcomemedicine.anatomical_structureItalyLower Extremity030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtymedicine.drug_classvenous thromboembolismHemorrhage03 medical and health sciencesSex FactorsdeathInternal medicinesuperficial vein thrombosiscohort studymedicineHumansAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryAnticoagulantsmedicine.diseaseSurgerymajor bleedingMultivariate AnalysisPulmonary Embolismbusinesscohort study; death; major bleeding; superficial vein thrombosis; venous thromboembolism; HematologyJournal of Thrombosis and Haemostasis
researchProduct

Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens

2014

To evaluate the concordance and prognostic role of histologic variants of bladder urothelial carcinoma in transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC) specimens. METHODS Clinicopathologic information available at the time of RC and follow-up data from 4110 RC specimens, collected between January 2000 and December 2009 at 17 tertiary referral centers were retrospectively analyzed and evaluated for the presence or absence of uncommon variants of bladder urothelial carcinoma. The presence or absence of uncommon variants of bladder urothelial carcinoma was evaluated on previous TURBT specimens of patients undergoing RC. Cox regression was used to assess the impac…

MaleURINARY-BLADDER; CANCER; UPDATE; IMPACT; DIFFERENTIATIONIMPACTmedicine.medical_treatmentKaplan-Meier EstimateSettore MED/24 - UrologiaRetrospective StudieBladder cancer histologic variantsbladder urothelial carcinomaUrinary bladderMedicine (all)Middle AgedPrognosisCANCERDIFFERENTIATIONmedicine.anatomical_structureTreatment OutcomeUrinary Bladder Neoplasmbladder cancerFemaleHumanmedicine.medical_specialtyPrognosiConcordanceUrologyUrinary BladderUrologyCystectomyDisease-Free SurvivalFollow-Up StudieCystectomymedicineCarcinomaHumansClinical significanceAged; Carcinoma; Cystectomy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urology; Medicine (all)Proportional Hazards ModelsRetrospective StudiesAgedBladder cancerProportional hazards modelbusiness.industryCarcinomaAged; Carcinoma; Cystectomy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder NeoplasmsCancermedicine.diseaseUrinary Bladder NeoplasmsProportional Hazards ModelUPDATEURINARY-BLADDERbusinessFollow-Up Studies
researchProduct

Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls

2011

Background: Immune perturbation likely affects the development of Kaposi sarcoma (KS) among people infected with the KS-associated herpesvirus (KSHV). We tested whether KSHV-seropositive individuals or cases of classic KS (cKS), which typically originates in the leg, had differing delayed-type hypersensitivity (DTH) in the forearm or leg. Methods: Mantoux DTH with three antigens (Candida, tetanus, PPD) was performed on the forearm and leg of 15 cKS cases, 14 KSHV-positives without KS, and 15 KSHV-negative controls. The diameters of induration responses were compared by group and body site. Results: Leg DTH was greater than forearm DTH among controls (mean difference 5.6 mm, P=0.0004), where…

MaleherpesvirusesCancer ResearchAllergyherpesvirusedelayed-type hypersensitivitySettore MED/42 - Igiene Generale E ApplicataForearmAntigenImmunopathologymedicineHumansHypersensitivity DelayedSarcoma KaposiAgedLegClassic Kaposi Sarcomaintegumentary systembusiness.industryKaposi sarcomamedicine.diseasebody regionsTransplantationForearmhuman immunodeficiency virus (HIV)medicine.anatomical_structureOncologyItalyDelayed hypersensitivityHerpesvirus 8 HumanImmunologyClinical StudyFemaleSarcomabusinesstransplantation
researchProduct

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting …

2010

The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNβ-1a) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (RRMS). Patients aged 18—50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score ≤4.0) were assigned IFNβ therapy at the physician’s discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNβ-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for c…

Maleinterferon beta-1aKaplan-Meier EstimateRelapsing-RemittingNeuropsychological TestsCohort StudiesDisability EvaluationMedicineMale; Adolescent; Young Adult; Middle Aged; Kaplan-Meier Estimate; Cognition Disorders; Survival Analysis; Female; Disability Evaluation; Dose-Response Relationship Drug; Humans; Multiple Sclerosis Relapsing-Remitting; Prospective Studies; Cohort Studies; Disease Progression; Interferon-beta; Injections Subcutaneous; Neuropsychological Tests; Adult; Immunologic Factors; Endpoint DeterminationProspective StudiesProspective cohort studyinterferon beta multiple sclerosis cognitive impairmentSubcutaneousCognitive disorderHazard ratioMiddle AgedSettore MED/26 - NEUROLOGIANeurologyDisease ProgressionSettore MED/26 - NeurologiaFemaleDrugmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentEndpoint DeterminationInjections SubcutaneousLower riskInjectionsDose-Response RelationshipYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicineHumansImmunologic Factorscognitive functioncognitive impairmentExpanded Disability Status ScaleDose-Response Relationship Drugbusiness.industryInterferon beta-1aMcDonald criteriaOdds ratioInterferon-betamedicine.diseaseSurvival AnalysisSurgerydisabilityNeurology (clinical)businessCognition Disorderscognitive function; cognitive impairment; disability; disease progression; interferon beta-1a; multiple sclerosis
researchProduct